S
Erik Harris
Senior Director, Sales and Marketing, Tysabri, Elan
IS BUSY WITH: Newborn twins
BIGGEST ACCOMPLISHMENT: The blockbuster growth of Rituxan
I'm a person that loves challenges," says Erik Harris. And it must be true—otherwise, he wouldn't be heading up the sales and marketing effort for Tysabri and it's new Crohn's Disease indication. "The safety issues, and the fact that patients and doctors have to enroll in a RiskMAP to be on it, make it a difficult product to sell," concedes Harris. "But it's worth it because, for some patients, there are no other options."
Erik Harris
Perhaps even more valuable than his previous work experience building the brands of Rituxan and Tarceva at Genentech, are the lessons Harris learned while serving as a naval aviator for the military. "If you can implement ideas and get people to move forward and change things in that bureaucratic system, well then, those skills translate."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.